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Reverse transcriptase and real-time polymerase chain reactions are widely used for the detection of gene overexpres-
sion. However, various disadvantages and limitations arise when the detection of multiple genetic targets is required. 
In previous studies, our laboratory successfully established a membrane array operation platform with a diagnostic 
biochip for the screening of gene overexpression by circulating tumor cells in cancer patients. To effectively shorten 
the reaction time, we improved the conventional RNA extraction method. The concept of weightedness was included 
in the reading procedure of the chip array and a weighted enzymatic chip array (WEnCA) platform was established. 
We used fluid engineering to develop a fully automatic gene chip analyzer named Chipball, which runs automatically 
on the WEnCA platform. The combination of the two systems is named the WEnCA-Chipball system. To understand the 
actual differences between the operations of WEnCA-Chipball and WEnCA-manual, we used the WEnCA-manual to 
analyze KRAS-associated gene overexpression in 200 samples from cancer patients to establish a cutoff value for acti-
vating the KRAS Detection Chip. Specifically, the activated KRAS expression in blood samples of 209 lung cancer 
patients was analyzed by both WEnCA-manual and WEnCA-Chipball and compared. The clinical applicability of WEnCA-
Chipball was defined, including the sensitivity, specificity, and accuracy. The results showed that among 209 samples, 
71 patients were positive for activated KRAS expression by WEnCA-Chipball with a sensitivity of 89%, specificity of 
94%, and accuracy of 92%. In addition, the average total score of WEnCA-Chipball was 4.7 lower than that of the 
WEnCA-manual. The WEnCA-Chipball required an operation time of only 7.5 hours, approximately one-ninth of the 
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WEnCA-manual operation time and one-fifth of the cost of WEnCA-manual. No significant difference was found 
between the detection limitations of the two systems. Great strides have been made in this development. The 
WEnCA-Chipball operation system has potential for clinical applications.
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reading, every gene is calculated by the same value; 
this does not differentiate the importance of each 
gene for specific disease diagnoses, a major limita-
tion of this technique in clinical application.14 For 
this study, the cost of the digoxigenin enzyme used 
on the colorimetric biochip platform was too high 
for laboratory diagnosis, and the high criteria of 
the operation techniques prevented its widespread 
availability for clinical applications. Therefore, we 
developed the next generation biochip operation 
platform (weighted enzymatic chip array [WEnCA]). 
The technical difference between the WEnCA sys-
tem and the conventional membrane array in-
cludes the different weighted multiples for each 
gene target on the biochip, dependent on the impor-
tance of each gene during the cancer development 
process. Further more, the conventional digoxigenin 
system was replaced by the biotin-avidin enzyme 
system to lower the cost (Figure 1). The manual op-
eration platform used has been successfully estab-
lished and published;15,16 the aim of the current 
study was to further establish an automatic system 
of WEnCA-Chipball by incorporating recently de-
veloped fluid engineering (Figure 2). As a result, the 
WEnCA platform may be automatically operated to 
effectively reduce the manual errors and limita-
tions due to technical criteria.
With the rapid advancements in the field of fluid 
engineering, and especially biomedicine in recent 
years, automated and rapid biomedical analysis is 
now considered to offer the greatest potential and 
market value.17,18 In terms of biomedical develop-
ment, the automated fluid biomedical test system 
that was produced through fluid engineering has the 
advantages of high detection sensitivity, portabil-
ity, low sample/test sample consumption, low power 
consumption, small size, and low cost. Compared 
with conventional analysis techniques, it represents 
a significant breakthrough. With a variety of inno-
vative techniques, a wide range of precision fluid 
components have been manufactured to control bi-
ological fluids, reduce the size of the biochemical 
analytical instruments, and integrate the processes 
into a one-step automated system that facilitates 
the rapid conducting of biomedical tests.11 In this 
experiment, the fluid engineering technique was 
adopted to automate the WEnCA platform, signifi-
cantly reduce detection time, and reduce errors 
Introduction
The analysis of gene overexpression has led to 
fundamental progress and clinical advances in the 
diagnosis of disease.1,2 The techniques that are 
commonly used to study gene overexpression in-
clude Northern blotting, and reverse transcriptase 
(RT) and real-time polymerase chain reactions 
(PCRs).3−5 Since Northern blotting involves com-
plex steps and a large numbers of samples, its ap-
plication is limited to research instead of clinical 
diagnosis. On the other hand, since RT-PCR and real-
time PCR are performed through a series of simple 
steps, they are applied extensively for the detec-
tion of single genes, including the hepatitis virus 
and other infectious pathogens.6,7 Although the in-
vention of PCR ranks as one of the great scientific 
inventions, most PCR techniques have a few com-
mon problems: (1) contamination, such as false-
positive results from oversensitive detection of, say, 
aerosolized DNA or previous sample carry-over; (2) 
RT-PCR is regarded as only semi-quantitative, since 
it is difficult to control the efficiency of sequence 
amplification when comparing different samples; 
and (3) interference is caused by annealing be-
tween the primers. RT-PCR or real-time PCR is used 
extensively in the detection of a single-gene tar-
get.8−10 For the detection of multiple targets or 
gene clusters, PCR-related techniques tend to be 
time-consuming, cumbersome, and costly.
The rapid development of biotechnology in re-
cent years has made biochips an important tool in 
clinical diagnosis or drug efficacy evaluation.11 Our 
previous study has developed and evaluated a 
membrane array-based method for simultaneously 
detecting the expression levels of multiple mes-
senger RNA (mRNA) markers from circulating cancer 
cells in the peripheral blood for cancer diagnosis.12 
In those studies, the expression levels of molecular 
markers were simultaneously evaluated by RT-PCR 
and membrane array. Data obtained from RT-PCR 
and membrane array were subjected to linear re-
gression analysis, revealing a high degree of cor-
relation between the results of these two methods 
(r = 0.979, p < 0.0001).13
The application of the membrane array for can-
cer diagnosis has been successfully proven in our pre-
viously studies. However, at the time of outcome 
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arising from human operation. Thus, the bottleneck 
that was preventing the commercialization of the 
chip detection technique has been overcome.
To understand the clinical applicability of WEnCA-
Chipball, and the resulting differences between the 
actual operations of WEnCA-Chipball and WEnCA-
manual, we first analyzed KRAS associated gene 
expression using the WEnCA-manual to establish 
the cutoff value for the Activating KRAS Detection 
Chip. Next, the activated KRAS expression in blood 
samples of 209 lung cancer patients was deter-
mined according to the experimental procedure 
shown in Figure 3. They were then analyzed by 
both WEnCA-manual and WEnCA-Chipball; the re-
sults were compared and the clinical applicability 
of WEnCA-Chipball was defined. Further compari-
sons were performed on the sensitivity, the specifi-
city, and the accuracy of the WEnCA manual and 
automatic operation platform. The application, op-
eration time, and cost of the two platforms were 
also investigated to evaluate the clinical application 
potential of WEnCA-Chipball.
Materials and Methods
Specimen collection
Initially, cancer tissues were collected from 200 se-
lected cancer patients enrolled in this study, in-
cluding 85 patients with breast cancer, 64 patients 
with colorectal cancer (CRC), and 51 patients with 
non-small cell lung cancer (NSCLC) who had under-
gone surgical resection or biopsy between January 
2007 and December 2008. The data from the 200 
cancerous patients were used for the analysis of 
sensitivity, specificity, and diagnostic accuracy of 
WEnCA. Tissue samples from various cancer patients 
were divided into two groups: one group of 100 
cancer tissues with the KRAS mutation (including 
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32 CRCs, 51 breast cancers, and 17 NSCLCs), and 
one group of 100 cancer tissues without the KRAS 
mutation (including 32 CRCs, 34 breast cancers and 
34 NSCLCs). These groups were used to determine 
the cutoff value of the WEnCA method for further 
circulating tumor cell analysis of 209 lung cancer 
patients. To clinically evaluate and compare both 
two systems, WEnCA-manual and WEnCA-Chipball, 
blood specimens from 209 lung cancer patients were 
collected within test tubes containing anticoagu-
lant sodium citrate. To avoid contamination of skin 
cells, the sampled blood was taken via an intrave-
nous catheter, plus the first few milliliters of blood 
were discarded. Total RNA was immediately extracted 
from the peripheral whole blood, and then served 
as a template for complementary DNA (cDNA) syn-
thesis. Sample acquisition and subsequent usage 
were approved by the institutional review boards 
of three hospitals. Written informed consent was 
obtained from all participants.
WEnCA-manual
Total RNA isolation and cDNA synthesis
Total RNA was isolated from the collected cancer tis-
sue specimens using the acid–guanidinium-phenol-
chloroform method according to standard protocol.19 
The RNA concentration was determined spectropho-
tometrically based on the absorbance at 260 nm. First-
strand cDNA was synthesized from total RNA using 
the Advantage RT-PCR kit (Promega, Madison, WI, 
USA) and reverse transcription was performed in a 
reaction mixture consisting of transcription optimized 
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buffer, oligo(dT)15 primer at 25 mg/mL 100mM PCR 
nucleotide mix, 200mM Moloney murine leukemia 
virus reverse transcriptase, and 25 mL of recombinant 
ribonuclease inhibitor. The reaction mixtures were 
incubated at 42ºC for 2 hours, heated to 95ºC for 
5 minutes, and then stored at 48ºC until analysis.
Weighted enzymatic chip array
The oligo chip preparation was the same as previ-
ously described.2,4,6,13 The labeling of the first 
cDNA and operating procedures for chip hybridiza-
tion were also the same as previously described; 
however, the probe labeling in this study used bi-
otin in place of digoxigenin. After hybridization, the 
chips were washed, blocked, and then incubated for 
30 minutes in horseradish peroxidase-conjugated 
donkey anti-rabbit immunoglobulin G (Amersham 
Pharmacia Biotech, Baie d’Urfe, Quebec, Canada), 
diluted in TRIS buffered saline. The blot was proc-
essed using the 3,3-diaminobenzidine kit (Amersham 
Pharmacia Biotech) according to the manufacturer’s 
instructions. The colorimetric signal was detected 
with an Alpha Innotech Image system (Alpha Innotech 
Corp., San Leandro, CA, USA), and the intensity of 
each spot on the membrane was measured using 
AlphaEase FC software (Alpha Innotech Corp). The 
criteria for determining the overexpressed spot are 
described elsewhere.2,4,6,13 Each positive spot was 
multiplied by different weighted values ranging from 
1 to 4 based on the performance after KRAS activa-
tion to calculate the total score of the chip.
WEnCA-Chipball system
mRNA extraction
Biotin poly(dT) and streptavidin magnetic beads 
were used to isolate the mRNA. First, the cells 
were disintegrated by adding lysis buffer to the 
blood samples. Magnetic glass particles were then 
added to combine with the RNA in the cells and 
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flush/separate the nucleic acids on the magnetic 
beads and buffer. After that, the mRNA was eluted 
and stored for later use.
Chipball operating procedure
First, to breakdown the blood cells and isolate 
mRNA, the fluid delivery control system delivers 
blood and lysis buffer to the first reaction chamber 
(sample preprocessing area) (Figure 4) through the 
fluid input area. The fluid delivery control system 
also delivers the ChargeSwitch Lysis Magnetic Beads 
(Invitrogen Corp., Carlsbad, CA, USA), binding buffer, 
and wash buffer through the fluid input area to the 
first chamber. The samples are mixed (eddy effect) 
by the spin tray on the active mixer device to en-
sure that the samples react effectively enough for 
the RNA to combine with the magnetic beads by 
means of an electric charge connection. The re-
acted samples and the beads that have absorbed 
mRNA onto the surface can then be delivered to 
the second reaction chamber (sample purification 
area) by the fluid delivery control system. Magnetic 
beads are used to separate and purify the targeted 
samples in this area. The reacted magnetic beads 
that have the samples absorbed onto their surface 
can be collected by the magnetism control system 
and transmitted to the wash buffer by the fluid de-
livery control system. The remaining waste liquid, 
except the beads containing mRNA, can be emitted 
by the fluid delivery control system through the 
waste collection area. The beads with absorbed 
RNA are then demagnetized, and the waste collec-
tion area is closed. The elution buffer is delivered 
through the fluid delivery control system to the re-
action area for the mixing reactions. The purified 
mRNA samples that have been extracted are then 
delivered through the fluid delivery control system 
and the fluid propellant area to the third reaction 
chamber (transcription), and then to the probe la-
beling area. The purified mRNA samples are then 
delivered to the reaction chamber for mixing reac-
tions through the fluid delivery control system. The 
reaction temperature needed by the transcription 
reaction can be regulated by the temperature con-
trol system, allowing the mRNA to be converted 
into stable cDNA for chromogen labeling on the bi-
omolecular test target. The reacted samples are 
then delivered by the fluid delivery control system 
through the buffer to the hybridization and color 
development area for the hybridization reaction. 
Meanwhile, before delivering the samples to the 
fourth reaction chamber (hybridization reaction 
area), the gene chips are placed in the hybridiza-
tion and color development area for the prehybrid-
ization reaction. The labeled cDNA samples then 
enter the fourth reaction chamber where the fluid 
reaction temperature needed for the hybridization 
reaction is regulated by the temperature control 
system and the ExpressHyb hybridization solution 
(Clontech Laboratories, Inc., Mountain View, CA, 
USA), biotin-labeling mixture, wash buffer, blocking 
buffer, streptavidin conjugation, detection buffer, 
3,3-diaminobenzidine, and double-distilled water is 
delivered through the fluid delivery control system. 
After completion of the hybridization reaction, the 
chip color can be extracted and processed by the 
image system and image/information processing 
system.
Assessment of the sensitivity of the 
WEnCA-Chipball system
The detection limitation of the WEnCA-manual and 
WEnCA-Chipball systems were evaluated by a dilu-
tion test. Samples of 100, 25, 12, and 5 H358 lung 
cancer cells were added to 5 mL of peripheral blood 
obtained from a healthy volunteer. After the cells 
were added to the blood samples, either the WEnCA-
manual or the WEnCA-Chipball system was used to 
perform the hybridization reaction by activating the 
KRAS Detection Chip. Next, the resultant reading was 
performed according to the description above, and 
the total score of the chip reaction was calculated.
Statistical analysis
All data were analyzed using the Statistical Package 
for Social Sciences version 11.5 (SPSS Inc., Chicago, 
IL, USA). The χ2 test was used to analyze the cor-
relation between the Activating KRAS Detection 
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Figure 4 Automatic microfluid reaction chamber design.
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Chip results from both the WEnCA-manual and the 
WEnCA-Chipball system. Correlations where p < 0.05 
were considered statistically significant.
Results
Determination of the cutoff value of the 
Activating KRAS Detection Chip by the 
WEnCA-manual method
To determine the cutoff value of the Activating 
KRAS Detection Chip by the WEnCA method, we 
analyzed 200 cancer tissues of which 100 had the 
KRAS mutation and the others had wild-type KRAS. 
The 200 tissues collected underwent mRNA extrac-
tion and first cDNA labeling before reacting to the 
Activating KRAS Detection Chip by the WEnCA-
manual method. After signal development, each 
gene spot density was normalized using the den-
sity of β-actin on the same chip. Next, the result 
obtained from the cancer tissue with KRAS muta-
tion was divided by the normalized value obtained 
from the sample spot of the tissue without mutant 
KRAS to obtain the ratio. A ratio higher than 2 was 
defined as being positive for gene overexpression. 
In terms of analysis using WEnCA, to determine the 
weighted value of each gene spot, we divided the 
percentage of each gene overexpression in the 100 
cancer tissues with the activating KRAS mutation 
to provide four classes (Figure 3). The gene spot 
that showed overexpression in over 80 cancer tis-
sues had a weighted value of 4 (3 in 70−80 cancer 
tissues, 2 in 60−70 cancer tissues, and 1 in 50−60 
cancer tissues). After the reaction through WEnCA, 
the positive gene spots were multiplied by their 
respective weighted values to obtain the total score 
of the chip. They then underwent analysis using the 
receiver operating characteristic curve with a pos-
itive reaction cutoff value of 20 (Figure 4). Results 
showed that the sensitivity reached 96% and the 
specificity reached 97%.
Detection limitation of the WEnCA-manual 
and WEnCA-Chipball assay
We evaluated the detection limitation of WEnCA-
manual and WEnCA-Chipball systems, with the ad-
dition of 100, 25 and 12 cancer cells that possessed 
the activated mutant KRAS into 5 mL of blood. These 
gave total scores higher than the cutoff value of 20 
in both systems, except when only six cells were 
added, in which case the total score equaled 8 
in WEnCA-manual and 5 in the WEnCA-Chipball sys-
tem (importantly, both lower than 20). No signifi-
cant differences were found between the detection 
limitations of the two systems (Figure 5).
Table 1  Mutant KRAS detected by Weighted Enzymatic 
Chip array (WEnCA)-manual and WEnCA-Chipball 
systems
WEnCA-manual
 WEnCA-Chipball
 Negative Positive Total
Negative 135 0 135
Positive 4 70  74
Total 139 70 209
Array
image
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+
42
+
38
+
30
−
8
+
37
100Cell numbers in5 mL blood. 25 12 6
+
32
+
26
−
5
WEnCA-
Chipball
Figure 5 Detection limitation of Weighted Enzymatic 
Chip array (WEnCA)-manual and WEnCA-Chipball systems.
Clinical assessment of the accuracy 
of WEnCA-manual and WEnCA-Chipball 
assays
To establish the capabilities of the two systems for 
the clinical detection of KRAS activation from 
blood samples, we collected 209 samples of pe-
ripheral blood from pathologically proven lung 
cancer patients. All specimens were tested with 
the Activating KRAS Detection Chip by both the 
WEnCA-manual and WEnCA-Chipball methods. The 
paired cancer tissue with KRAS mutational status 
then served as the reference standard. The ana-
lytic results are shown in Table 1. There were 71 
cancer tissues with KRAS mutation. Among them, 
66 were positive through WEnCA-manual and 63 
through WEnCA-Chipball. Moreover, among the 138 
paired cancer tissues with wild-type KRAS, 130 
were negative through both WEnCA-manual and 
WEnCA-Chipball assays. After statistical analysis, 
the sensitivity of the WEnCA-manual reached 93% 
and the specificity reached 94% (Table 2). On the 
other hand, the sensitivity through WEnCA-Chipball 
decreased to 89% and the specificity remained at 
94%. Using WEnCA-Chipball, the average total score 
of the positive sample was 6.1 lower and the average 
total score of the negative sample was 3.9 lower. 
The overall average total score was 4.7 lower than 
the WEnCA-manual (Table 3).
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Regarding operation time, the WEnCA-Chipball 
required only 7.5 hours whereas the WEnCA-manual 
required 3 days, approximately nine times the 
time required for the automated system. Regarding 
operational cost, the cost of the WEnCA-manual was 
US$80 per sample, including the administration fee, 
which was approximately five times more than that 
of WEnCA-Chipball.
Discussion
In recent years, target therapy has been exten-
sively applied in addition to conventional chemo-
therapy and radiotherapy in the treatment of lung 
cancer, colorectal cancer, and breast cancer.19−21 
The KRAS mutations of cancer cells were determined 
using the membrane array technique which was es-
tablished in our earlier research.14 Direct detection 
of the overexpression of activated KRAS in periph-
eral blood is an indicator for target therapy such as 
cetuximab or gefitinib.22 However, the highly tech-
nical criteria of chip operation and the complicated 
reading of the conventional method hinders its wide-
spread availability to general clinics. Therefore, the 
current study successfully developed the WEnCA-
Chipball to effectively solve those problems.
The results showed more consistent detection 
results compared with the original membrane 
array method while maintaining the same level of 
accuracy. In the WEnCA-Chipball system, the total 
operation time from input of samples to comple-
tion of the image analysis was about 7.5 hours, 
a substantial decrease in time compared with the 
3 days required for the manually operated membrane 
array. In addition, human errors were substantially 
reduced. Evidently, the WEnCA-Chipball system not 
only provides an innovative automatic system for 
clinical target therapy efficacy evaluation, but also 
improves the clinical usability and accuracy com-
pared with the manual method. Thus, our study 
shows that it is a practical means to assess the 
drug efficacy of clinical target treatment.
With regard to the application of fluid engi-
neering techniques in the chip platform, the Lab-
on-a-Chip,23 developed by Micro-fluid Systems, is 
the most widely known. However, after 5 years of 
research, even though micro-fluidic chips have 
been extensively studied, the assessment of its 
clinical applications and the interpretation of re-
sults have not been possible; therefore, the clini-
cal applications remain limited.24,25 However, the 
WEnCA-Chipball system developed by this research 
team not only retains the advantages of the lab-
on-a-chip device, but also overcomes the problem 
of the micro-fluidic chip’s unsuitability for contin-
uous operation and linkage to an interpretation 
system. As the world’s first automatic chip analyzer, 
it will be useful in the future for the molecular di-
agnosis of infectious diseases, the detection of cir-
culating tumor cell through chip replacements, or 
the assessment of drug efficacy.
In this study, we compared the total scores of 
activated KRAS expression of the same sample 
using both the Activating KRAS Detection Chip with 
WEnCA-manual and the WEnCA-Chipball. The re-
sults showed that the average score detected by 
WEnCA-Chipball was 4.7% lower than using WEnCA-
manual. The decreased genetic expressions may be 
caused by the shortened hybridization time with 
the WEnCA-Chipball method, which was 1/15th of the 
manual operation time. In addition, among all of the 
tested samples, the sensitivity of the automatic sys-
tem decreased by 4%. This was possibly due to the 
cutoff value used by WEnCA-Chipball being gener-
ated by the WEnCA-manual, which had a higher 
average detection score. Therefore, samples with 
scores distributed around the threshold value may 
be positive using the WEnCA-manual method, but 
negative using the WEnCA-Chipball method. To re-
solve this problem, an independent receiver operat-
ing characteristic curve can be precisely calculated 
by WEnCA-Chipball to obtain a lower cutoff value.
The WEnCA-Chipball system, through a built-in 
computer system, not only instantly produces the 
results of traditional chip analysis, but also con-
nects to a global network. The detection results 
Table 3  Comparison of KRAS mutant detection ana-
lyzed by Weighted Enzymatic Chip array 
(WEnCA)-manual and WEnCA-Chipball systems
 Mean score Difference
 WEnCA- WEnCA- (Chipball − 
 manual Chipball Manual)
Positive specimens 46.1 40 −6.1
Negative specimens 13.8 9.9 −3.9
Total specimens 25.2 20.6 −4.6
Table 2  Sensitivity, specificity and accuracy of the 
Weighted Enzymatic Chip array (WEnCA)-Chipball 
and WEnCA-manual systems*
KRAS
 WEnCA-Chipball (WEnCA-manual)
 Negative Positive Total
Wild-type 130 (130) 8 (8) 138
Mutation 8 (5) 63 (66)  71
Total 138 (135) 71 (74) 209
*The sensitivity of WEnCA-manual was 93%, WEnCA-Chipball was 
89%; specificity was 94% in both and the accuracy was 94% in 
the WEnCA-manual and 92% in the WEnCA-Chipball.
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and probe points can be transmitted across the 
world using common software. All the probe net-
works around the world can be completed through 
the prevalent Chipball-WEnCA system. Our study 
shows that the Chipball-WEnCA system can have 
extensive applications in clinical medicine and 
holds great potential for future development.
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